AICoin AI: Eli Lilly’s $2.75B Bet on AI Drug Development Mirrors Crypto Funding Models
Pharmaceutical giant Eli Lilly has committed up to $2.75 billion to license AI-developed drug candidates from Insilico Medicine, signaling growing institutional adoption of generative AI in biotech. The deal includes a $115 million upfront payment with the remaining value tied to milestones—a structure reminiscent of crypto project funding rounds where initial capital unlocks development phases.
Insilico's pipeline includes 28+ AI-generated therapeutics, with nearly half already in clinical trials. This mirrors the rapid iteration seen in blockchain projects like Ethereum's Layer 2 solutions or Solana's high-throughput ecosystem, where technical milestones trigger further investment.
The partnership may indirectly benefit AI-focused crypto projects (FET, AGIX, OCEAN) as institutional validation of generative AI accelerates. Pharmaceutical companies increasingly resemble crypto VCs—placing multiple bets on emerging tech, with payouts weighted toward successful outcomes.